Jun 2026 (Q2 FY26) — Aug 5, 2026
Myomo Q2 FY26 — Strong Revenue Growth Driven by Recurring Patient Sources, Raised FY Guidance
Read the full callMyomo (MYO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Myomo earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 11.7 | +21.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -19.3 | +28.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -4.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.25 +4.17% · +$0.05
Performance +21.4% 1Y
1Y: $1.03 on 17 Oct 2025 → $1.25. High $1.86 (19 Aug 2026), low $0.64 (30 Mar 2026).
- Previous close
- $1.2
- 52-week range
- $0.64 – $1.86
- One year
- +11.61%
Overview
- Symbol
- MYO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Myomo earnings calls (MYO)
Financials
What the filings say
Net profit, year on year: +13% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 12 | 10 | 10 | 10 | 11 | 10 | 12 |
| Operating profit | -1 | -0 | -4 | -5 | -4 | -3 | -3 | -2 |
| Operating margin | −10.4% | −2.0% | −35.8% | −47.6% | −34.9% | −24.4% | −31.2% | −19.3% |
| Profit before tax | -1 | -0 | -3 | -4 | -4 | -4 | -3 | -4 |
| Tax rate | −9.6% | −48.4% | −4.1% | −3.3% | −3.9% | −2.3% | −6.6% | −0.8% |
| Net profit | -1 | -0 | -3 | -5 | -4 | -4 | -3 | -4 |
| EPS ($ per share) | -0.03 | — | -0.08 | -0.11 | -0.09 | — | -0.07 | -0.09 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -45 | -56 | -68 | -78 | -89 | -97 | -103 | -119 |
| Total liabilities | 2 | 5 | 3 | 5 | 4 | 6 | 18 | 27 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Investments | — | — | — | — | 0 | 2 | 0 | 4 |
| Total assets | 8 | 7 | 15 | 20 | 10 | 15 | 42 | 39 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10 | -10 | -9 | -10 | -10 | -6 | -3 | -15 |
| Cash from investing | -0 | -0 | -0 | -0 | -0 | -2 | 0 | -7 |
| Cash from financing | 3 | 8 | 17 | 13 | 0 | 10 | 21 | 11 |
| Net cash flow | -6 | -2 | 8 | 3 | -10 | 2 | 18 | -10 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -2 |
| Free cash flow | -10 | -10 | -9 | -10 | -10 | -6 | -5 | -16 |
Insider filings
54 filings between Nov 18, 2025 and Oct 13, 2026.
Open market
decisions to buy or sellPurchases
$442.4K
13 purchases by 4 insiders
Sales
$181.5K
6 sales by 3 insiders
Compensation
not trading decisions- 23
- Award — granted as compensation
- 12
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| KIRK THOMAS F | $200.3K | — | Jun 5, 2026 |
| Manko Joseph M. Jr. | $173.9K | — | May 15, 2026 |
| Kovelman Harry | — | $82.7K | Sep 11, 2026 |
| Mitchell Micah | — | $77.7K | May 14, 2026 |
| Getz Heather C | $64.9K | — | Mar 16, 2026 |
| Morris Milton Mayo | — | $21.1K | Sep 2, 2026 |
| Crowley Thomas Aloysius Jr. | $3.2K | — | Nov 19, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 13, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 71,250 | $0 |
| Oct 13, 2026 | HENRY DAVID A Chief Financial Officer | Award | 51,250 | $0 |
| Oct 13, 2026 | Kovelman Harry Chief Medical Officer | Award | 32,500 | $0 |
| Oct 12, 2026 | McClure Mary-Katherine Hale Chief Commericial Officer | Award | 275,000 | $0 |
| Oct 12, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 3,133 | $4.3K |
| Oct 9, 2026 | HENRY DAVID A Chief Financial Officer | Award | 6,272 | $0 |
| Oct 9, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 8,363 | $0 |
| Sep 11, 2026 | Kovelman Harry Chief Medical Officer | Sale | 15,844 | $20.1K |
| Sep 2, 2026 | Morris Milton Mayo Director | Sale | 15,000 | $21.1K |
| Aug 20, 2026 | Kovelman Harry Chief Medical Officer | Sale | 17,500 | $30.3K |
| Aug 7, 2026 | Kovelman Harry Chief Medical Officer | Tax withheld | 22,457 | $31.9K |
| Aug 7, 2026 | HENRY DAVID A Chief Financial Officer | Award | 68,644 | $0 |
| Aug 7, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 25,310 | $35.9K |
| Aug 7, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 146,909 | $0 |
| Aug 7, 2026 | Mitchell Micah Chief Commercial Officer | Award | 58,409 | $0 |
| Aug 7, 2026 | Mitchell Micah Chief Commercial Officer | Tax withheld | 21,559 | $30.6K |
| Aug 7, 2026 | Kovelman Harry Chief Medical Officer | Award | 55,149 | $0 |
| Jul 13, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 5,166 | $5.6K |
| Jul 10, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 10,454 | $0 |
| Jul 10, 2026 | HENRY DAVID A Chief Financial Officer | Award | 7,840 | $0 |
| Jun 25, 2026 | Morris Milton Mayo Director | Award | 78,704 | $0 |
| Jun 25, 2026 | FEBBO WILLIAM J Director | Award | 78,704 | $0 |
| Jun 25, 2026 | KIRK THOMAS F Director | Award | 78,704 | $0 |
| Jun 25, 2026 | Getz Heather C Director | Award | 78,704 | $0 |
| Jun 25, 2026 | Crowley Thomas Aloysius Jr. Director | Award | 78,704 | $0 |
| Jun 25, 2026 | Manko Joseph M. Jr. Director | Award | 78,704 | $0 |
| Jun 12, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 10,969 | $0 |
| Jun 12, 2026 | Mitchell Micah Chief Commercial Officer | Tax withheld | 9,061 | $10.9K |
| Jun 12, 2026 | Kovelman Harry Chief Medical Officer | Tax withheld | 10,442 | $12.5K |
| Jun 8, 2026 | Kovelman Harry Chief Medical Officer | Tax withheld | 7,635 | $10.2K |
| Jun 8, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 10,050 | $0 |
| Jun 8, 2026 | Mitchell Micah Chief Commercial Officer | Tax withheld | 6,529 | $8.7K |
| Jun 5, 2026 | KIRK THOMAS F Director | Purchase | 40,002 | $50.8K |
| May 28, 2026 | KIRK THOMAS F Director | Purchase | 25,000 | $24.8K |
| May 28, 2026 | Kovelman Harry Chief Medical Officer | Sale | 11,536 | $11.7K |
| May 27, 2026 | Kovelman Harry Chief Medical Officer | Sale | 20,464 | $20.5K |
| May 18, 2026 | KIRK THOMAS F Director | Purchase | 43,401 | $39.5K |
| May 15, 2026 | Manko Joseph M. Jr. Director | Purchase | 30,367 | $27.0K |
| May 15, 2026 | KIRK THOMAS F Director | Purchase | 31,605 | $28.7K |
| May 14, 2026 | Mitchell Micah Chief Commercial Officer | Sale | 90,231 | $77.7K |
| May 14, 2026 | Manko Joseph M. Jr. Director | Purchase | 170,830 | $146.9K |
| Apr 14, 2026 | FEBBO WILLIAM J Director | Award | 45,000 | $0 |
| Apr 13, 2026 | HENRY DAVID A Chief Financial Officer | Tax withheld | 3,953 | $2.8K |
| Apr 10, 2026 | HENRY DAVID A Chief Financial Officer | Award | 12,500 | $0 |
| Apr 10, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 16,666 | $0 |
| Mar 16, 2026 | Getz Heather C Director | Purchase | 20,000 | $14.0K |
| Mar 13, 2026 | KIRK THOMAS F Director | Purchase | 72,000 | $51.1K |
| Mar 12, 2026 | Getz Heather C Director | Purchase | 70,000 | $51.0K |
| Jan 12, 2026 | GUDONIS PAUL R Chief Executive Officer | Award | 11,637 | $0 |
| Jan 12, 2026 | HENRY DAVID A Chief Financial Officer | Award | 8,727 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MYOMO, INC.
Free account. Everything above stays public.
Write why you follow MYOMO, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading